Development of autoimmune nephritis in genetically asplenic and splenectomized BAFF transgenic mice

Journal of Autoimmunity

Volumn 36, Issue 2, 2011, Pages 125-134

  Fletcher, Carrie A ^a   Groom, Joanna R ^a   Woehl, Blanche ^a   Leung, Helen ^a   Mackay, Charles ^b   Mackay, Fabienne ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Autoimmunity; B cells; BAFF; Inflammation; Nephritis; Spleen

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE NEPHRITIS; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; INNATE IMMUNITY; KIDNEY; LYMPHOCYTIC INFILTRATION; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; SALIVARY GLAND; SIGNAL TRANSDUCTION; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNIZATION; LYMPH NODES; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEPHRITIS; PNEUMOCOCCAL VACCINES; RHEUMATOID FACTOR; SPLEEN; SPLENECTOMY;

EID: 79951948210     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.12.002     Document Type: Article

References (48)

1. Mackay F., Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009, 9:491-502.
2. Mackay F., Browning J.L. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002, 2:465-475.
3. Mackay F., Schneider P., Rennert P., Browning J.L. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
4. Mackay F., Groom J.R., Tangye S.G. An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol 2007, 19:406-413.
5. Mackay F., Silveira P.A., Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007, 19:327-336.
6. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453-1465.
7. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
8. Gross J.A., Dillon S.R., Mudri S., Johnston J., Littau A., Roque R., et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15:289-302.
9. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease [see comments]. Nature 2000, 404:995-999.
10. Vora K.A., Wang L.C., Rao S.P., Liu Z.Y., Majeau G.R., Cutler A.H., et al. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 2003, 171:547-551.
11. Hardy R.R., Hayakawa K. B cell development pathways. Annu Rev Immunol 2001, 19:595-621.
12. Goodnow C.C., Cyster J.G., Hartley S.B., Bell S.E., Cooke M.P., Healy J.I., et al. Self-tolerance check points in B cell development. Adv Immunol 1995, 59:279-369.
13. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
14. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
15. Hoffman R.W. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 2004, 113:4-13.
16. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J., et al. BAFF and MyD88 signals promote a lupus-like disease independent of T cells. J Exp Med 2007, 204:1959-1971.
17. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002, 109:59-68.
18. Batten M., Fletcher C., Ng L., Groom J., Wheway J., Laâbi Y., et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphomas. J Immunol 2004, 172:812-822.
19. Fletcher C.A., Sutherland A.P., Groom J.R., Batten M.L., Ng L.G., Gommerman J., et al. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur J Immunol 2006, 36:2504-2514.
20. Wardemann H., Boehm T., Dear N., Carsetti R. B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen. J Exp Med 2002, 195:771-780.
21. Dear T.N., Colledge W.H., Carlton M.B., Lavenir I., Larson T., Smith A.J., et al. The Hox11 gene is essential for cell survival during spleen development. Development 1995, 121:2909-2915.
22. Roberts C.W., Shutter J.R., Korsmeyer S.J. Hox11 controls the genesis of the spleen. Nature 1994, 368:747-749.
23. Reeves J.P., Reeves P.A. Survival surgery: removal of the spleen and the thymus. Current protocols in immunology 1991, 1.10.11-11.10.11. Wiley Interscience, New York. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Stober (Eds.).
24. Srivastava B., Quinn W.J., Hazard K., Erikson J., Allman D. Characterization of marginal zone B cell precursors. J Exp Med 2005, 202:1225-1234.
25. Martin F., Kearney J.F. Marginal-zone B cells. Nat Rev Immunol 2002, 2:323-335.
26. Schneider P., Mackay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., et al. BAFF, a novel ligand of the tumor necrosis factor (TNF) family, stimulates B-cell growth. J Exp Med 1999, 189:1747-1756.
27. Berland R., Wortis H.H. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002, 20:253-300.
28. Mackay F., Sierro F., Grey S.T., Gordon T.P. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005, 8:243-265.
29. Zandvoort A., Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 2002, 130:4-11.
30. Duan B., Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 2006, 5:403-408.
31. Hoek K.L., Gordy L.E., Collins P.L., Parekh V.V., Aune T.M., Joyce S., et al. Follicular B cell trafficking within the spleen actively restricts humoral immune responses. Immunity 2010, 33:254-265.
32. Ratner M. Human genome sciences trial data wow lupus community. Nat Biotechnol 2009, 27:779-780.
33. Takeuchi T., Tsuzaka K., Yoshimoto K., Kamda H., Amano K. T cell abnormalities in systemic lupus erythematosus. Autoimmunity 2005, 38:339-346.
34. Vinuesa C.G., Cook M.C., Angelucci C., Athanasopoulos V., Rui L., Hill K.M., et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005, 435:452-458.
35. Thatayatikom A., White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006, 5:18-24.
36. Kessel A., Rosner I., Toubi E. Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 2008, 34:74-79.
37. Pillai S., Cariappa A., Moran S.T. Marginal zone B cells. Annu Rev Immunol 2005, 23:161-196.
38. Bao L., Osawe I., Haas M., Quigg R.J. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 2005, 175:1947-1955.
39. Schuster H., Martin T., Marcellin L., Garaud J.C., Pasquali J.L., Korganov A.S. Expansion of the marginal zone B cells is not sufficient for the development of renal disease in NZBxNZW F1 mice. Lupus 2002, 11:277-286.
40. Amano H., Amano E., Moll T., Marinkovic D., Ibnou-Zekri N., Martinez-Soria E., et al. The Yaa mutation promoting murine lupus causes defective development of marginal zone B cells. J Immunol 2003, 170:2293-2301.
41. Daridon C., Pers J.O., Devauchelle V., Martins-Carvalho C., Hutin P., Pennec Y.L., et al. Identification of transitional type II B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006, 54:2280-2288.
42. Hansen A., Odendahl M., Reiter K., Jacobi A.M., Feist E., Scholze J., et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002, 46:2160-2171.
43. Alugupalli K.R., Leong J.M., Woodland R.T., Muramatsu M., Honjo T., Gerstein R.M. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 2004, 21:379-390.
44. Gorelik L., Cutler A.H., Thill G., Miklasz S.D., Shea D.E., Ambrose C., et al. BAFF regulates CD21/35 and CD23 expression independently of its B cell survival function. J Immunol 2004, 172:762-766.
45. Ng L.G., Ng C.H., Woehl B., Sutherland A.P., Huo J., Xu S., et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur J Immunol 2006, 36:1837-1846.
46. Mackay F., Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008, 19:263-276.
47. He B., Santamaria R., Xu W., Cols M., Chen K., Puga I., et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010, 11:836-845.
48. Jacobi A.M., Huang W., Wang T., Freimuth W., Sanz I., Furie R., et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010, 62:201-210.